Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
10.72
-0.51 (-4.54%)
At close: Nov 20, 2026, 4:00 PM EST
10.86
+0.14 (1.32%)
After-hours: Nov 20, 2026, 7:42 PM EST
Gossamer Bio Employees
As of December 31, 2025, Gossamer Bio had 162 total employees, including 161 full-time and 1 part-time employees. The number of employees increased by 17 or 11.72% compared to the previous year. That makes Gossamer Bio the 28,268th largest employer in the world and 3,563rd in the United States.
Employees
162
Change (1Y)
17
Growth (1Y)
11.72%
Revenue / Employee
$484,093
Profits / Employee
-$772,062
Market Cap
65.57M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 162 | 17 | 11.72% | 161 | 1 |
| Dec 31, 2024 | 145 | 10 | 7.41% | 144 | 1 |
| Dec 31, 2023 | 135 | -43 | -24.16% | 135 | 0 |
| Dec 31, 2022 | 178 | -7 | -3.78% | 178 | 0 |
| Dec 31, 2021 | 185 | -11 | -5.61% | 185 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Tenaya Therapeutics | 70 |
| Neumora Therapeutics | 60 |
| Cardiff Oncology | 31 |
| NeurAxis | 24 |
| Tenax Therapeutics | 16 |
| MAIA Biotechnology | 13 |
| Atara Biotherapeutics | 10 |
GOSS News
- 6 days ago - Gossamer Bio registers to sell 1.7M shares of common stock for holders - TheFly
- 6 days ago - Gossamer Bio Registration statement: Registration filing - Filings
- 11 days ago - Gossamer Bio price target lowered to $96 from $120 at Piper Sandler - TheFly
- 12 days ago - Gossamer Bio reports Q3 EPS ($7.36), consensus ($3.93) - TheFly
- 12 days ago - Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 12 days ago - Gossamer Bio Quarterly report: Q3 2026 - Filings
- 12 days ago - Gossamer Bio Earnings release: Q3 2026 - Filings
- 5 weeks ago - Gossamer Bio initiated with a Buy at Chardan - TheFly